## PATENT/OFFICIAL

\_SHEET \_1\_OF \_1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)			SBL-001IIS	ATTY. DOCKET NO. SBL-001US		SERIAL NO. 09/892,613	
			APPLICANT Shawn Shui-on LEUNG				
				FILING DATE June 27, 2001		GROUP 1643	
		U.S. PATENT	DOCUMENTS				
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
EXAMINER'S INITIALS	PATENT NO.	DATE COU	JNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
	OTHER	ART (Including Author,	Title, Date, Perti	nent Pages, Etc	.)		
/DB/	Fiona ADAIR, "Immunogenicity: The Last Hurdle for Clinically Successful Therapeutic Antibodies", <i>BioPharm</i> , pp. 42-46 (October 2000).  Man Sung CO et al., "Humanized Antibodies for Antiviral Therapy", <i>PNAS USA</i> , Vol. 88: 2869-2973 (April 1991).						
	Elvin A. KABAT et al., "Identical V Region Amino Acid Sequences and Segment of Sequences in Antibodies of Different Specificities", <i>Journal of Immunology</i> , Vol. 147 (5): 1709-1719 (September 1991).						
	Eduardo A. PADLAN, "Anatomy of the Antibody Molecule", <i>Molecular Immunology</i> , vol 31 (3): 169-217 (1994).						
/DB/	Tai Te WU et al., "Possible Use of Similar Framework Region Amino Acid Sequences Between Human and Mouse Immunoglobulins for Humanizing Mouse Antibodies", <i>Molecular Immunology</i> , Vol. 29 (9): 1141-1146 (1992).						
			***				
EXAMINER	/David Bland	chard/	DATE CONSID	DERED 08/16	/2007		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

1 of

Sheet

PTO/SB/088 (02-03)
Approved for use through 04/30/2003. OMB 0651-0031

David Blanchard

655-US

Under the Peperwork Reduction Act of 1995, no persons er	0.5. Fale reguired to respond to a collection	nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of Information unless it contains a valid OMB control number.		
ibstitute for form 1449/PTO	Complete if Known			
	Application Number	09/892,613		
NFORMATION DISCLOSURE	Filing Date	June 27, 2001		
STATEMENT BY APPLICANT	First Named Inventor	Shawn Shui-on LEUNG		
(Use as many sheets as necossary)	Art Unit	1642		
toon me many anone as mecusary)	Examiner Name	David Blasshand		

**Attorney Docket Number** 

Examiner	Cite	OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
DR	4	Complaint for Declaratory Judgment and Permanent Injunction (Civil	
		Action No. 2471-N), including Exhibits A-G	
<del>-DD</del> -	2-	Motion for Special Process Servers (Civil Action No. 2471-N), and Order Appointing Special Process Servers (Civil Action No. 2471-N)	
DB	3	Supplemental Information Rusuant to Rule 3(a) of the Rules of the Court of Chancery	
		·	
		·	
			_

l Examiner		Date	
	l /m / 2 m 2	Date	10/11/0000
Signature	/David Blanchard/	Commissioner	12/11/2006
0.9.1010.0	,	Considered	///
			<b>b</b>

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Transiation is attached.

This collection of Information is required by 37 CFR 1.99. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, OC 20231.